Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 2/20 | 0.33 |
| ▸ | FNTB | P49356 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.32 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMO | Q99835 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL883070 | 0.89 | KMT2A (0.39) | KMT2AHTR1ADRD2HTR2ARAB9A | |
| SCHEMBL12306493 | 0.85 | CCR1 (0.39) | KMT2ACCR1CCR5CCR8NOS3 | |
| SCHEMBL15070844 | 0.77 | CYP11B1 (0.31) | — | |
| SCHEMBL30849369 | 0.76 | FNTA (0.33) | KMT2AFNTAFNTB | |
| SCHEMBL12696414 | 0.76 | CASP1 (0.46) | NOS3NOS1NOS2FNTAFNTB | |
| SCHEMBL29207149 | 0.76 | FNTA (0.33) | KMT2AFNTAFNTB | |
| SCHEMBL30849370 | 0.76 | FNTA (0.33) | KMT2AFNTAFNTB | |
| SCHEMBL16043515 | 0.76 | DYRK1A (0.35) | KMT2APTGS2FNTAFNTBSRD5A1 | |
| SCHEMBL568921 | 0.76 | PTGS1 (0.39) | KMT2APTGS2FNTAFNTBPDK2 | |
| SCHEMBL15074614 | 0.74 | PARP10 (0.51) | KMT2APARP10PARP11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742106-B2 | Disubstituted heteroaryl-fused pyridines | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| US-8742106-B2 | Disubstituted heteroaryl-fused pyridines | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| US-8742106-B2 | Disubstituted heteroaryl-fused pyridines | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| EP-2516437-B1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2014-01-29 | — | — | EP | disclosed |
| EP-2516437-B1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2014-01-29 | — | — | EP | disclosed |
| EP-2516437-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | Novartis AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| US-20120258973-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| US-20120258973-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| US-20120258973-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| WO-2011076744-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076744-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258973-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | CYP4F2, CYP11B2, CYP4F3 | KMT2A 2606/4885PTGS2 261/4885CCR1 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.